Abstract:Fatima Karzai ^ , Ravi A. Madan, William D. Figg Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA ^ ORCID: 0000-0002-3244-1332. Comment on: Fizazi K, Piulats JM, Reaume MN, et al . Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med 2023;388:719-32. Keywords: Rucaparib; prostate cancer; BRCA ; metastatic Submitted Aug 28, 2023. Accepted for publication Dec 12, 2023. Published online Jan 12, 2024. doi: 10.21037/tcr-23-1563 In the ongoing quest for precision medicine solutions to intricate oncologic challenges, Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have risen to prominence in metastatic prostate cancer in patients that harbor BRCA mutations with the Food and Drug Administration (FDA) approvals of olaparib and rucaparib. In the TRITON-3 clinical trial, Fizazi et al. presents the results of a randomized, open-label phase 3 study of patients with metastatic castrate-resistant prostate cancer (mCRPC) with a BRCA1/2 or ATM mutations who had disease progression with a novel hormonal therapy (NHT) which included abiraterone, enzalutamide, apalutamide or an investigational agent (1). Taxane-based therapy or an NHT for castrate-sensitive disease was permitted. Patients were assigned in a 2:1 ratio to receive the oral PARP inhibitor, rucaparib at 600 mg by mouth twice daily, or physician's choice of docetaxel or NHT: abiraterone or enzalutamide. The primary outcome was radiographic progression-free survival (rPFS), according to an independent review. Of note, crossover to receive rucaparib was permitted after disease progression was confirmed by an independent review. In this international trial, 405 patients had deleterious BRCA or ATM alterations, 270 underwent randomization to the rucaparib group, and 135 patients were randomized to the physician's choice group. The results show at 62 months, the median rPFS was longer in the rucaparib group compared to the physician's choice group in the BRCA subgroup, 11.2 vs. 6.4 months [hazard ratio (HR), 0.50; 95% confidence interval (CI): 0.36 to 0.69], and the intention-to-treat (ITT) population, 10.2 vs. 6.4 months (HR, 0.61; 95% CI: 0.47 to 0.80). While P<0.001 for both comparisons, in the ATM subgroup, the results were not as robust with median rPFS of 8.1 months (95% CI: 5.5 to 8.3) in the rucaparib group vs. 6.8 months in the control group (95% CI: 4.0 to 10.4). Secondary outcomes included median overall survival (OS), wherein the BRCA subgroup, OS was 24.3 months (95% CI: 19.9 to 25.7) vs. 20.8 months (95% CI: 16.3 to 23.1) in the control group (HR, 0.81; 95% CI: 0.58 to 1.12; P=0.21). Patient reported outcomes were assessed from baseline to week 25 on the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire. Interestingly, in the BRCA subgroup and the ITT population, changes in the score were similar for rucaparib and the control medications. The most common adverse events (AEs) reported for patients treated with olaparib were fatigue, nausea, and anemia, while in the control group, the most common AEs were fatigue, diarrhea, and neuropathy. For grade 3 and above, anemia, neutropenia, and fatigue were seen in the rucaparib group vs. fatigue and neutropenia in the control group. No myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) cases were reported with rucaparib treatment. In the setting of mCRPC, the success of an individualized approach to treatment has varied particularly dependent on genetics. In 2015, Robinson et al. conducted a prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from 150 patients with mCRPC (2). Alterations in BRCA1/2 and ATM were identified at higher frequencies than anticipated, with analysis of somatic and pathogenic alterations in BRCA2 in 19/150 cases (12.7%). From identifying alterations that were potentially actionable in the DNA damage repair (DDR) pathways, further research indicated the PARP inhibitor olaparib had anti-tumor activity in mCRPC in patients with aberrations in the DDR genes based on a composite endpoint with the highest number of responses again in the BRCA1/2 subgroup (3). When selecting patients with mCRPC for treatment with PARPi, after treatment and progression on enzalutamide or abiraterone, data from the phase 3 PROfound study evaluating single-agent olaparib showed rPFS was longer in the olaparib group in patients with at least one alteration in BRCA1/2 or ATM vs. physician's choice of enzalutamide or abiraterone (7.4 vs. 3.6 months; HR, 0.34; 95% CI: 0.25 to 0.47; P<0.001) (4). The median OS in t -Abstract Truncated-

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR)

TMPRSS2:ERG Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer

Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

How far does a new horizon extend for rucaparib in metastatic prostate cancer?

Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors

A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).

Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes

Abstract PR014: Genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR).

Abstract B138: Pharmacodynamics-driven phase 2 trial of talazoparib in patients with advanced solid tumors and aberrations in genes involved in DNA damage response

Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2

Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial

A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer

A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update.

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis